Hansoh Pharmaceutical (3692) Announces NMPA Acceptance of New Drug Application

Bulletin Express02-27 20:25

Hansoh Pharmaceutical Group Company Limited (3692) announced that on February 27, 2026, the National Medical Products Administration accepted the New Drug Application for Dalmelitinib Mesylate Tablets in combination with Aumolertinib Mesylate Tablets (Ameile). The combination targets locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer whose tumors have mesenchymal to epithelial transition factor amplification after prior EGFR tyrosine kinase inhibitor therapy.

Dalmelitinib Mesylate Tablets, designated as HS-10241, is an orally administered c-MET tyrosine kinase inhibitor developed by the Group. The acceptance marks a key milestone toward expanding treatment options for these advanced-stage cancer patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146971038?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146971038","market":"us","top_or_hot":-1,"title":"Hansoh Pharmaceutical (3692) Announces NMPA Acceptance of New Drug Application","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (3692) announced that on February 27, 2026, the National Medical Products Administration accepted the New Drug Application for Dalmelitinib Mesylate Tablets in combination with Aumolertinib Mesylate Tablets (Ameile). The combination targets locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer whose tumors have mesenchymal to epithelial transition factor amplification after prior EGFR tyrosine kinase inhibitor therapy.</p>\n<p>Dalmelitinib Mesylate Tablets, designated as HS-10241, is an orally administered c-MET tyrosine kinase inhibitor developed by the Group. The acceptance marks a key milestone toward expanding treatment options for these advanced-stage cancer patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharmaceutical (3692) Announces NMPA Acceptance of New Drug Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharmaceutical (3692) Announces NMPA Acceptance of New Drug Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-27 20:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (3692) announced that on February 27, 2026, the National Medical Products Administration accepted the New Drug Application for Dalmelitinib Mesylate Tablets in combination with Aumolertinib Mesylate Tablets (Ameile). The combination targets locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer whose tumors have mesenchymal to epithelial transition factor amplification after prior EGFR tyrosine kinase inhibitor therapy.</p>\n<p>Dalmelitinib Mesylate Tablets, designated as HS-10241, is an orally administered c-MET tyrosine kinase inhibitor developed by the Group. The acceptance marks a key milestone toward expanding treatment options for these advanced-stage cancer patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1146971038","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146971038","pubTimestamp":1772195146,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (3692) announced that on February 27, 2026, the National Medical Products Administration accepted the New Drug Application for Dalmelitinib Mesylate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"豪森药业(3692)公布NMPA受理新药申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (3692) announced that on February 27, 2026, the National Medical Products Administration accepted the New Drug Application for Dalmelitinib Mesylate Tablets in combination with Aumolertinib Mesylate Tablets (Ameile). The combination targets locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer whose tumors have mesenchymal to epithelial transition factor amplification after prior EGFR tyrosine kinase inhibitor therapy.\nDalmelitinib Mesylate Tablets, designated as HS-10241, is an orally administered c-MET tyrosine kinase inhibitor developed by the Group. The acceptance marks a key milestone toward expanding treatment options for these advanced-stage cancer patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146971038","isCrawlerRequest":true}